title: Soluble HLA class I and class II molecules in relapsing-remitting multiple sclerosis: acute response to interferon-beta1a treatment and their use as markers of disease activity.
abstract: During relapses in relapsing-remitting multiple sclerosis (RRMS), serum soluble HLA class I surface antigen (sHLA-I) levels are reported to either decrease or remain unchanged, whereas serum sHLA-II levels increase. Interferon-beta1b therapy was recently reported to increase serum sHLA-I in RRMS. In the present prospective study, solid-phase enzyme-linked immunosorbent assay was used to measure sHLA-I and sHLA-II in the sera of 21 RRMS patients during a clinical exacerbation, and then six weeks after treatment with high-dose interferon-beta1a (IFN-beta1a). Pretreatment serum sHLA-I was significantly lower in patients than in normal controls (P < 0.0005). Pretreatment sHLA-II was also significantly lower than in normal controls (P = .003) unless enhancing MRI lesions (objectified relapse) were present; then sHLA-II levels were similar to normal controls (relative increase). Six weeks after initiation of IFN-beta1a treatment, a significant increase in serum sHLA-I was observed in all 21 RRMS patients (P < .0005). Conversely, serum sHLA-II decreased significantly after treatment in the entire patient group (P < .0005). The acute effect of IFN-beta1a on serum sHLA-I and sHLA-II was observed to be the opposite of that occurring during RRMS relapses. Monitoring of both sHLA-I and sHLA-II appears necessary if these molecules are to be developed as RRMS activity markers.
authors.affiliation: Department of Neurology, Louisiana State University Health Sciences Center, 1501 Kings Highway, Shreveport, LA 71130, USA.
authors.forename: Alireza
authors.initials: A
authors.lastname: Minagar
authors.forename: Irena
authors.initials: I
authors.lastname: Adamashvilli
authors.forename: Stephen L
authors.initials: SL
authors.lastname: Jaffe
authors.forename: Michael F
authors.initials: MF
authors.lastname: Glabus
authors.forename: Eduardo
authors.initials: E
authors.lastname: Gonzalez-Toledo
authors.forename: Roger E
authors.initials: RE
authors.lastname: Kelley
mesh_terms: D000328:Adult; D015415:Biomarkers; D005260:Female; D015395:Histocompatibility Antigens Class I / Q000097:blood*; D000949:Histocompatibility Antigens Class II / Q000097:blood*; D006801:Humans; D016899:Interferon-beta / Q000627:therapeutic use*; D008297:Male; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000276:immunology*; D012008:Recurrence
chemical_list: D015415:Biomarkers; D015395:Histocompatibility Antigens Class I; D000949:Histocompatibility Antigens Class II; D016899:Interferon-beta